CD274 and hepatocellular carcinoma: In a syngeneic orthotopic animal model of HCC, we demonstrated that silencing these two targets promotes single agent antitumor activity and, at lower doses, demonstrated that they can augment the activity of anti-PDL1 antibody in this model, possibly by increasing T-cell penetration into the tumor.